Answers are grounded in this paper and cite their sources.
Background Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no curative therapy. Neuroinflammation, glial overactivation, neuromuscular junction (NMJ) damage and neuronal apoptosis are major pathological features of ALS. Mesenchymal stem cell-derived small extracellular vesicles (MSC-sEVs) are neuroprotective and anti-inflammatory and can cross the blood-brain barrier. Here, we investigated the therapeutic efficacy and systemic safety of intranasal MSC-sEVs in ALS mice. Methods sEVs were isolated from mesenchymal stem cells using anion exchange chromatography, and then lyophilized. The bioactivity of lyophilized MSC-sEVs was validated in a LPS-induced BV2 microglial inflammation model. The SOD1 G93A mice were administered by nasal administration, and motor function was assessed by grip strength and rotarod tests. Neuromuscular junction (NMJ) integrity in the gastrocnemius muscle was examined by immunofluorescence. Neuroinflammation and mitochondrial function-related proteins in the spinal cord and cerebral cortex were detected by western blot and immunofluorescence. Public transcriptomic datasets were used to explore the correlation between SYF2 and ALS-related molecular signatures and its regulatory role in mitochondrial gene expression. For safety evaluation, male and female C57BL/6 mice were also treated via intranasal administration, body weight, serum liver and kidney biochemical parameters, and liver and kidney histology were assessed. Results MSC-sEVs significantly ameliorated motor dysfunction in ALS mice, protected NMJ integrity, inhibited microglial and astrocyte overactivation, and reduced neuroinflammation. SYF2 was upregulated in ALS patients and correlated with DNA damage-related pathways, while SYF2 silencing upregulated multiple mitochondrial genes enriched in oxidative phosphorylation, suggesting that SYF2 may modulate mitochondrial gene expression in ALS. Safety verification showed that MSC-sEVs caused no adverse effects on mouse growth or liver and kidney function and even improved liver biochemical parameters, showing favorable biosafety. Conclusions Intranasal MSC-sEVs effectively alleviate neuroinflammation, preserve NMJ integrity and rescue motor impairment in ALS mice, with reliable systemic safety. The preserved bioactivity of lyophilized MSC-sEVs and the involvement of SYF2-mediated mitochondrial regulation support MSC-sEVs as a safe and promising translatable therapeutic candidate for ALS.
No takes yet. Share an insight, caveat, or question.
王树汉 et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: